Studies Introducing Costimulation Blockade for Vascularized Composite Allografts in Nonhuman Primates

Area of Science:

• Transplantation immunology
• Regenerative medicine

Background:

• Vascularized composite allografts (VCAs) offer reconstructive potential but face significant challenges.
• Conventional immunosuppression, particularly calcineurin inhibitors, presents toxicity and incomplete efficacy issues in VCA transplantation.
• Acute rejection remains a major hurdle in VCA recipients, despite current treatment options.

Purpose of the Study:

• To evaluate the efficacy of costimulation blockade, alone and in combination with adhesion blockade, in a nonhuman-primate VCA model.
• To assess the potential of B7-specific costimulation blockade to mitigate rejection without the adverse effects of calcineurin inhibitors.
• To determine the adjunctive role of LFA3-Ig in combination with costimulation blockade in VCA transplantation.

Main Methods:

• Utilized a nonhuman-primate model for vascularized composite allografts.
• Administered immunosuppressive regimens including B7-specific costimulation blockade (belatacept) with and without LFA3-Ig.
• Compared outcomes to tacrolimus-based immunosuppression.
• Assessed allograft survival, T cell populations (CD2(hi) memory T cells), and histological findings using Banff grading.

Main Results:

• Belatacept improved rejection-free allograft survival compared to tacrolimus.
• The combination of belatacept and LFA3-Ig reduced CD2(hi) memory T cells but did not enhance allograft protection.
• The addition of LFA3-Ig impaired protective immunity.
• Histological findings correlated with clinical observations and Banff grading.

Conclusions:

• Costimulation blockade with belatacept demonstrates promise for improving VCA survival by mitigating rejection.
• Combining belatacept with LFA3-Ig may not offer additional benefits for rejection prophylaxis and could compromise protective immunity.
• These findings support further investigation of costimulation blockade strategies in VCA transplantation using relevant preclinical models.